Denali Therapeutics sees cash runway into 2028
Source: SeekingAlpha
2025-01-13 12:32:12 ET
More on Denali Therapeutics
- Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
- Denali Has A Neurodegenerative Edge Despite Market Skepticism
- Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome
- Denali ALS candidate fails in key study
- Seeking Alpha’s Quant Rating on Denali Therapeutic
Read the full article on Seeking Alpha
For further details see:
Denali Therapeutics sees cash runway into 2028
Maptelligent Inc
NASDAQ: MAPT
MAPT Trading
0.0% G/L:
$0.0001 Last:
7,500 Volume:
$0.0001 Open:
MAPT Latest News
MAPT Stock Data
$750,000
771,860,607
N/A
3
N/A
Software & IT Services
Technology
US
Henderson
